SNY Stock Analysis: Buy, Sell, or Hold?
SNY - Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
$47.04
0.84 (1.82%)
▲
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Jan 29, 2026
0d
Get Alerted When SNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called SNY this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: SNY shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: SNY shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$61.50
Based on 4.5% avg growth
INTRINSIC VALUE TODAY
$38.19
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNY is currently trading at $47.04, which is considered slightly low relative to its 30-day fair value range of $46.67 to $48.47. The stock's valuation (Forward PE: 9.0) is in line with its historical norms (9.6). Remarkably, the market is currently pricing in an annual earnings decline of 2.2% over the next few years. This pessimistic expectation contrasts with the company's recent 2.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SNY is showing sideways momentum. The price is approaching resistance at $47.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $58.08 (+25.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SNY is showing sideways momentum. The price is approaching resistance at $47.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $58.08 (+25.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$46.67 -
$48.47
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.7% below Wall St target ($58.08)
Fair Price Analysis
30-Day Fair Range
$46.67 -
$48.47
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$45.25
Resistance Level
$47.89
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
8.99
Wall Street Target
$58.08
(+25.7%)
Revenue Growth (YoY)
-7.0%
Earnings Growth (YoY)
2.4%
Profit Margin
19.8%
Valuation Discount vs History
-2.2% cheaper
PE vs Historical
9.0 vs 9.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.2%
(market-implied from PE analysis)
1-Year Target
$45.18
(-2%)
2-Year Target
$44.19
(-4%)
3-Year Target
$43.22
(-7%)
3-Yr Target (if PE normalizes)
(PE: 9→10)
$46.17
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 5.0%)
$132.89
(+188%)
Base:
(SPY PE: 9.0, Growth: 5.0%)
$53.55
(+16%)
Bear:
(PE: 7.6, Growth: 5.0%)
$45.52
(-2%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (15x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 14.53 | Current EPS (TTM): $3.15
Bull Case
$82.17
(+75%)
Analyst growth 63.2%, PE expands to 16.0
Base Case
$74.70
(+59%)
Market implied 63.2%, PE stable at 14.5
Bear Case
$31.12
(-34%)
Severe decline -20.0%, PE contracts to 12.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.0 to 9.6
Stabilization Target:
$49.35
(+6.8%)
PE Expansion Potential:
+6.8%
Last updated: January 30, 2026 6:02 PM ET
Data refreshes hourly during market hours. Next update: 7:02 PM
Data refreshes hourly during market hours. Next update: 7:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1111 | 60 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$135 | 63 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$332 | 66 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$245 | 61 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$192 | 58 HOLD |
Advanced SNY Option Strategies
Professional options setups generated by AI based on today's SNY price and gamma walls.
